37 results about "Rocuronium" patented technology

Processes are provided herein for the preparation and purification of stable, powdered solids comprising substantially pure rocuronium bromide.

Provided is a method for reprocessing neuromuscular blocking agents containing a quaternary ammonium salt, e.g., Rocuronium bromide, using a novel dealkylation method. The process is effective in obtaining a highly pure product from a contaminated starting material by heating, optionally in the presence of an organic solvent, to produce a dealkyated product. The dealkylated product is purified, e.g., by crystallization, and converted by any known method to a stable, highly-pure neuromuscular blocking agent.

A novel process for preparing (2β,3α,5α,16β,17β)-17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane, a known intermediate in the synthesis of the skeletal muscle relaxant rocuronium bromide, is disclosed.

The invention discloses a stable rocuronium injection preparation prescription and a preparation method thereof. The injection contains the active ingredient rocuronium, a stabilizer, an osmotic pressure regulator, a pH (potential of Hydrogen) regulator and injection water, and has two specifications, i.e., 2.5 ml:25 mg and 5ml:50 mg. Rocuronium is added into the proper stabilizer, so that the problem of stability is solved; autoclave sterilization of 121 DEG C is adopted with the help of a filtration sterilization mode to guarantee the sterility. The preparation has the advantages of reasonable prescription, simple process and stable quality and is suitable for industrial production. The injection is used for muscular relaxation of surgical patients.

The invention provides a stable rocuronium bromide composition for vein, which contains rocuronium bromide with treating effective dose, EDTA-2Na-Ca or EDTA-2Na and a pH value buffer system. The EDTA-2Na-Ca or the EDTA-2Na delays the hydrolysis of a rocuronium bromide 17-bit ester bond of the composition in the processes of preparation and storage; and on one hand, medicine liquid can resist the high temperature in the processes of hot press and sterilization, on the other hand, the content of rocuronium bromide deacetyl impurities in the composition in the process of storage is reduced. The invention also provides a reasonable method for preparing the medicine liquid, which can reduce the generation of the rocuronium bromide hydrolysis impurities in the process of preparation. The reduction of the rocuronium bromide hydrolysis impurities improves the quality controllability of the composition and ensures the safety and effectiveness of clinical use.

The invention belongs to the technical field of medical chemistries, and particularly discloses a preparation method of high-purity high-stability rocuronium bromide. The preparation method comprises the following steps: performing pretreatment on a rocuronium bromide crude product by adopting aluminium oxide for removing most 3-bromopropylene, filtering, dropwise adding an obtained filtrate into diethyl ether stirred violently, wherein during adding process, a great amount of white solid separates out, dissolving the obtained white solids into a dilute acetic acid solution, rapidly freezing the solution into ice, and freeze drying, thus forming the rocuronium bromide. The preparation method provided by the invention has the advantages that the problems that a residual solvent in the prior art exceeds standard, the 3-bromopropylene is hard to remove, and the impurity content is high are successfully solved, and the obtained rocuronium bromide has the high purity and good stability.

The invention pertains to the medicinal chemosynthesis field and relates to the preparation method of 1-square bracket 17Beta-acetoxyl-3Alpha-oxhydryl-2Beta-(4-morpholinyl)-androstane-16Beta-group square bracket-1-(2-propenyl) pyrrole bromide (rocuronium). The preparation method adopts 2Alpha, 3Alpha, 16Alpha, 17Alpha-diepoxy-5Alpha-androstane-17Beta-glycol acetate as the raw material from which the rocuronium is obtained after seven reaction steps including hydrolysis, pyrrole reaction, morpholinyl reaction, etherification, reduction, acetylation, hydrolysis and quaterisation. The preparation method of the invention has the advantages that the hydrolysis of 16Alpha, 17Alpha-epoxy-17Beta-acetoxyl takes place at a comparatively low temperature, which can avoid the ring opening of the epoxy and further the inhibition of the formation of 17Alpha-(1-pyrrolidine)-16-ketone; the synthesis avoids the optional acetylation of site 3 and site 17 oxhydryls and clearly simplifies the separation after reaction.

The invention relates to a high-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4- morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or a composition thereof, a preparation method thereof (a compound shown in a formula III) or a composition thereof and application thereof to preparing rocuronium (a compound shown in a formula I). The method has good effect, low cost, high quality and simple and convenient operation and is suitable for large-scale industrial production; and the obtained product has high purity and stable properties.

The invention relates to a rocuronium bromide-containing injection. The injection is prepared from rocuronium bromide serving as an active ingredient and a pharmaceutically-acceptable carrier as accessories. The pH value of a system is maintained by adding a 1-5 percent acetate buffer solution, so that the stability of the solution is enhanced, the pH value of a system is maintained at the same time, degradation of main medicaments in a preparation process is suppressed, the stability of the main medicaments is enhanced, and the quantity of rocuronium bromide impurities C in an autoclave sterilizing process is reduced. Finally, a rocuronium bromide injection which has high stability and stable quality and is suitable for storing for a long time is obtained.

The invention discloses a method for preparing rocuronium bromide injection. The method includes steps of cooling injection liquid to the temperature lower than 25 DEG C, adding and dissolving sodium acetate in the injection and regulating a pH (potential of hydrogen) value of the solution to range from 3.8 to 4.2 by glacial acetic acid; adding and dissolving a prescription amount of rocuronium bromide crude drugs into the solution and regulating a pH value of the solution to range from 3.8 to 4.2; adding sodium chloride to condition the solution until the solution is hypertonic; and filtering the solution via a microporous membrane with the aperture of 0.22 micrometer. 1ml of the injection contains, by weight, 10mg of the rocuronium bromide, 2.0mg of sodium acetate, a proper amount of sodium chloride and a proper amount of glacial acetic acid. The method is simple in process, and the quality of the product is stable.

The invention relates to the field of analytical chemistry and discloses a method for detecting the content of bromopropylene in rocuronium bromide. Particularly, the method comprises the following steps of: taking a rocuronium bromide sample and dissolving the rocuronium bromide sample by using mixed solution with a volume ratio of acetonitrile to water of (9-6):(1-4) as a solvent to obtain tested solution; taking a bromopropylene reference substance and dissolving the bromopropylene reference substance by taking the mixed solution with the volume ratio of acetonitrile to water of (9-6):(1-4) as the solvent to obtain reference substance solution; respectively carrying out high-efficiency liquid chromatography detection on the reference substance solution and the tested solution; and analysing a measuring result by an external standard method. The method for detecting the content of the bromopropylene in the rocuronium bromide can be used for detecting the content of the bromopropylene in a rocuronium bromide product and has the limit of detection of 0.044ng. Due to the establishment of the method, in the process of preparing the rocuronium bromide, the residual amount of the bromopropylene can be detected. The method has high sensitivity, strong specificity and accurate and reliable results, so that the quality of the rocuronium bromide product is accurately evaluated and thequality of the rocuronium bromide product is ensured.

A rocuronium bromide injection solution-prefilled syringe of the present invention includes a syringe comprising an outer cylinder made of synthetic resin, a gasket which is accommodated inside the outer cylinder and liquid-tightly slidable inside the outer cylinder, and a seal member for sealing a distal end opening of the outer cylinder; and a rocuronium bromide injection solution filled inside the syringe. The gasket is formed by vulcanized chlorinated butyl rubber added calcined clay, and said calcined clay is only added as an inorganic filler classified as an inorganic reinforcing agent and an inorganic filling agent.

The invention discloses a drying method of a rocuronium raw material medicine for injection, and belongs to the technical field of raw material medicine preparation. The drying method of the rocuronium raw material medicine for the injection is characterized in that a rocuronium crude product is dissolved in an organic solvent with the boiling point lower than 60 DEG C to form a crude product solution, neutral alumina with the weight being 0.9 to 1.2 times of that of the rocuronium crude product is added into the crude product solution and stirred for 1h to 2h, then a filtrate filtered through a coarse filter and a fine filter for two times enters a temperature control tank, the temperature in the temperature control tank is kept at 10 to 35 DEG C, the residence time of the temperature control tank is 5min to 15min, then the filtrate is atomized into droplets through an atomizer and blown into a drying tower at the temperature of 50 to 80 DEG C to evaporate the solvent and form fine powder, and the fine powder is collected from a bottom discharge port after being separated through a cyclone separator to obtain the rocuronium raw material medicine for the injection. The drying method of the rocuronium raw material medicine for the injection successfully uses a spray drying process to replace the traditional vacuum oven drying and vacuum freeze-drying production process.

The invention discloses a preparation method for rocuronium bromide injection in a low impurity level. In a preparation process of the rocuronium bromide injection, the content of an impurity C is reduced to 0.1% as possible, and the condition that the impurities of the rocuronium bromide injection do not exceed a standard (a shelf life standard: 1.5%) within a validity period is guaranteed. Whilebacterial endotoxin of a raw material and an auxiliary material is controlled, activated carbon does not need to be added in a prescription process for performing a pyrogen removing operation, and the bacterial endotoxin of a finished product of the rocuronium bromide injection is still qualified. A temperature of prepared chemical is reduced, dissolved oxygen in solution is removed by nitrogen aeration and a solution pH value in the preparation process is reduced, the content of the impurity C is helpful to reduce, and the stability of the rocuronium bromide injection is helpful to improve.

The invention belongs to the technical field of biological medicine, and specifically relates to a preparation method and a pharmaceutical composition of rocuronium bromide. The preparation method ischaracterized by adding trichloromethane and water under a low-temperature condition, adding a certain amount of CO2, and adding diethyl ether for crystallization, thus obtaining a purified rocuroniumbromide raw material. After stability study is carried out on the raw material, increment of the contents of an impurity A and an impurity C of the raw material is less; in addition, the content of 3-bromopropylene (allyl bromide) in the raw material is smaller than 10ppm; an injection solution is prepared from the rocuronium bromide raw material obtained through the preparation method, the injection solution accords with all standards of a pharmacopoeia, and the increment of the impurity A, the impurity C and total impurity is remarkably lower than those in a commercially available product after cold-thermal cycling.

The invention relates to the technical field of medicines and chemical industry, discloses a preparation method of an important intermediate of rocuronium bromide, namely 16beta-tetrahydropyrrolyl androstan-2alpha-epoxy-17-one. The preparation method comprises the following steps: (1), in a ball milling tank, adding 17-acetoxy androstan-2alpha,16alpha-bisepoxide, pyrrolidine and silica gel, and reacting at a certain mechanical grinding frequency; and (2), post-treating a reaction mixture, and recrystallizing to obtain the 16beta-tetrahydropyrrolyl androstan-2alpha-epoxy-17-one. The preparationmethod has the advantages of high reaction yield, short time, high selectivity, simple and convenient operation, less pollution and the like, and is an environment-friendly chemical synthesis methodwith relatively good popularization and application prospects.

The invention discloses a rocuronium bromide enantiomeric impurity, a salt, a solvate, an enantiomer or a diastereoisomer of the rocuronium bromide enantiomeric impurity and a method for preparing the same. The rocuronium bromide enantiomeric impurity is shown as a formula V. An R1 and an R2 in the formula V are independently selected from H and acetyl; an R3 is selected from N-pyrrolidyl and N-allyl pyrrolidyl. The invention further provides application of the rocuronium bromide enantiomeric impurity to detecting the quality of rocuronium bromide intermediates, crude drugs or preparations. The rocuronium bromide enantiomeric impurity, the salt, the solvate, the enantiomer or the diastereoisomer, the method and the application have the advantages that gaps in the aspect of research on rocuronium bromide impurities can be filled, and foundations and bases can be provided for controlling the quality of rocuronium bromide materials or drugs.